Delivery Order SPE2DB20D2104-SPE2DB21FT69W

Award Date 8/17/21
Potential Completion Date 8/18/21
Potential Value $30K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $12,938.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $7,918.17 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,691.88, is for the delivery of Xifaxan 550 mg tablets. This is a Delivery Order contract with a Firm Fixed Price pricing type, with a completion date of December 6, 2023. The contract is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $27,596.05 delivery order covers the supply of the medication Xifaxan 550 mg tablets. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Amerisourcebergen's parent company, Cencora, Inc., which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $1,992.03 Firm Fixed Price delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to...
This federal contract award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a major pharmaceutical distributor, with the Defense Logistics Agency (DLA) Troop Support Medical. The $14,823.58 delivery order is for 60 tablets of the medication Xifaxan 550 mg. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., is the prime contractor for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,658.63, is for the delivery of Xifaxan 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00. This IDC serves as the primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $77,289.79, is for the delivery of Xifaxan 550 mg tablets. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, which has a potential value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary...
This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical is for the delivery of Xifaxan 550 mg tablets to support military and veterans' healthcare programs. The $8,613.32 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award, valued at $37,247.17, is for the delivery of Xifaxan 550 mg tablets. The contract has a period of performance through September 27, 2023 and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB21FT69W
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,406.52 delivery order is for the supply of Xifaxan 550 mg tablets. The contract is a firm fixed-price Delivery Order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Amerisourcebergen's parent company, Cencora, Inc. This IDC, valued at up to $999,999,999.00, serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen's extensive pharmaceutical distribution capabilities and its position as a key vendor for federal healthcare programs, particularly within the Department of Defense and Department of Veterans Affairs, enable it to efficiently fulfill government contracts for essential medical commodities.

Generated 2/27/25, 12:36 PM